SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its RAD 101 Phase 2b imaging trial, sparking significant community discussion around the potential for a short squeeze and high price targets. The stock's impressive pre-market surge and subsequent volatility have traders weighing the potential for further gains against the risk of a pullback. A forthcoming webinar is adding to the anticipation, with many speculating on its impact on the stock's direction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, driven by sector-wide concerns about an AI bubble and delayed data center projects, despite a major Microsoft deal. Community sentiment is divided, with some calling the stock a "scam" and expecting further declines, while others view the dip as a buying opportunity, citing strong fundamentals and long-term growth potential. Discussions also revolve around potential market manipulation and the stock's correlation with Bitcoin's price movements.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a potential short squeeze, with community members discussing high trading volume and a tight float. Optimistic traders are setting high price targets, while others caution about volatility and potential pullbacks. The stock's connection to AI-powered robotics and recent contract news may also be contributing to the heightened interest.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other HK stocks that have seen explosive runs. Community members are highlighting the company's recent acquisitions and revenue, anticipating news that could catalyze a significant price movement. Some traders caution against FOMO due to the stock's volatility and low volume.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending as community members discuss the potential impact of autonomous driving tests and analyst upgrades. Bullish sentiment is fueled by the possibility of Tesla achieving new highs, while bears express concerns about valuation. Options activity and overall market conditions are also contributing to the conversation around the stock.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's stock is trending amid discussions around its AI strategy and potential partnerships, particularly after some analysts suggested it's lagging behind competitors. The community is debating whether Apple's lower AI spending is a strength or weakness, with some viewing it as a safe haven play. Additionally, there's speculation about Apple's next moves in response to increasing competition and evolving market dynamics.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest news of a potential $19.5 billion write-down related to its EV strategy, with community discussions focusing on the implications of scaling back EV investments and shifting towards hybrids. Some view this pullback as a pragmatic move aligning with current market demand and improving profitability, while others question the company's leadership and long-term EV commitment. Broader conversations include the impact on Tesla and potential industry-wide EV write-downs.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending as investors anticipate a potential FDA approval for Narsoplimab by late December, with the community actively discussing the likelihood of approval and potential buyout scenarios. Recent price action and large put buys have sparked speculation about a possible news leak or market manipulation. Bullish investors express confidence in the drug's efficacy and Novo Nordisk's backing, viewing any price dips as buying opportunities.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a mix of AI sector excitement and volatility driven by broader market concerns and crypto price movements; the community is actively debating the stock's potential amidst discussions of data center demand and power dynamics, while some traders express frustration with the stock's trading pattern and perceived manipulation, and some suggest it is tied to Bitcoin's performance.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following FDA Fast Track designation for its AlloNK cell therapy in refractory rheumatoid arthritis, sparking community discussion around the potential impact and future data releases. The community is also discussing the company's financial health and upcoming data in November and is debating potential price movements. The stock is seeing increased attention, with some analysts raising price targets, and the community speculates on both short-term gains and long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.</li><li>The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.</li><li>Some of the symptoms of ichthyosis vulgaris include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or stomach.</li></ul>Azitra Inc. (AZTR) on Monday announced positive preclinical data for its ATR-01 program, which is designed to treat ichthyosis vulgaris, a skin disorder that most often appears in early childhood.<h2 class="st-heading-2">Ichthyosis Vulgaris Affects 1.3 Million People In The U.S.</h2>Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder. The company noted that ichthyosis vulgaris impacts 1.3 million people in the U.S., who have no treatment options apart from managing the symptoms.<blockquote>“We are optimistic that this innovative, topically delivered treatment option has the potential to directly address the disease pathophysiology. We look forward to further updates on this program in 2026, including details around a path to first-in-human studies."– Francisco Salva, CEO, Azitra</blockquote><a href="https://stocktwits.com/symbol/AZTR">Azitra shares</a> soared more than 56% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Is Ichthyosis Vulgaris?</h2>Ichthyosis vulgaris is a common skin disorder that causes dry, scaly skin. Some of the symptoms include severe dry skin and scales, which can appear on the face, back of the arms, legs, back, or the stomach,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://my.clevelandclinic.org/health/diseases/21069-ichthyosis-vulgaris">according</a> to the Cleveland Clinic. Some of the options available to manage these symptoms include frequent moisturization using topical exfoliants or oral retinoids in severe cases.Get updates to this story developing <a href="https://stocktwits.com/news-articles/markets/equity/azitra-shares-soar-premarket-positive-preclinical-data-ichthyosis-vulgaris/ch6CHUIR3Ym">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-up-major-earnings-week/ch6CM53R3Yh">Dow Futures Edge Up As Investors Turn Attention To Major Earnings Week: AMZN, BA, NVDA, ZION Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Azitra Shares Soar Pre-Market: What’s Driving The Surge?

Azitra stated that its data showed positive outcomes as the company advances towards a first-in-human clinical trial of the skin disorder.

Equity

Azitra had its best trading day in more than seven months on Wednesday after disclosing that the first patient had been dosed in its Phase 1/2 trial of ATR04-484, a topical live biotherapeutic being developed to treat rashes caused by EGFR inhibitor (EGFRi) cancer therapies.The stock closed Wednesday up 35.9% at $1.03, before slipping 2.4% in after-hours trading.ATR04-484, which has a fast-track designation from the FDA, is designed to address EGFRi-associated rash, a side effect that affects an estimated 150,000 people in the U.S. each year.&nbsp;These rashes are one of the most common and disruptive side effects of EGFRi cancer drugs, occurring in up to 80% of patients and often severe enough to interrupt treatment.“Dosing the first patient is an important milestone in the advancement of ATR04-484 as a potential treatment for EGFRi-associated rash,” said CEO Francisco Salva. He noted the therapy could help reduce the dermatologic toxicities that limit&nbsp;the use of targeted cancer therapies such as those for lung and colorectal cancers.The randomized, double-blind, vehicle-controlled Phase 1/2 study will evaluate ATR04-484’s safety, tolerability, and efficacy in adult patients, measuring endpoints such as rash severity, itch, and pain.&nbsp;The drug is based on an engineered strain of Staphylococcus epidermidis, designed to reduce IL-36γ and S. aureus levels, both of which are elevated in EGFRi-related rashes.Beyond ATR04-484, Azitra is also advancing ATR-12 for Netherton syndrome, a rare and life-threatening genetic skin disease with no approved therapies. Both programs stem from the company’s dermatology platform, which leverages a microbial strain library and artificial intelligence to identify new drug candidates.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,657% surge in 24-hour message volume.One user said that Azitra shares had been “holding pretty strong,” while others pointed to the surge in trading activity.&nbsp;<stembedurl>https://stocktwits.com/TheStocksDoc/message/626774494</stembedurl><stembedurl>https://stocktwits.com/Thunderman/message/626784109</stembedurl>Wednesday’s turnover reached 110.7 million shares, more than 800 times the stock’s average daily volume of about 132,000.<a href="https://stocktwits.com/symbol/AZTR">Azitra’s stock</a> has declined 63.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Azitra’s stock (AZTR) has declined 63.7% so far in 2025. (Photo credit: Getty Images)

Azitra Stock Scores Best Day In 7 Months After First Patient Dosed In Cancer-Linked Skin Rash Trial

The FDA has granted the program Fast Track status, aiming to address rashes that affect roughly 150,000 U.S. patients each year.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday morning after it announced two developments on Tuesday. The firm said the US Patent and Trademark Office (USPTO) has granted a patent that covers future potential pipeline candidates for indications including atopic dermatitis.Apart from this, the company also announced three additional newly allowed patents in three countries, including the US, Canada, and China. Following the announcement, the stock had closed over 200% higher on Tuesday. However, a large portion of the gains were pared in Wednesday’s pre-market session with the stock losing over 75% ahead of the market open.Following the development, the stock gained a lot of traction on Stocktwits. Tuesday’s page views for the symbol on Stocktwits stood at 220x their daily average of the previous month. Total user messages on the Azitra symbol page grew from a handful per day to over 1,000 on Tuesday while total number of users with the stock symbol on their watchlist grew by nearly 1,000 to roughly 1,600 as of Wednesday morning.The firm expressed optimism about its new patents. Azitra’s COO and co-founder Travis Whitfill pointed out that atopic dermatitis affects approximately 16.50 million people in the United States. “There are numerous diseases associated with filaggrin deficiency, and the newly issued U.S. patent extends our protection to include a major market in the U.S., atopic dermatitis, particularly those with mild to moderate disease. Additionally, the new patent allowances in China and Canada extend our IP strength globally,” he said.Meanwhile, the firm also announced a $10 million fundraise via common shares and warrants priced at $1.50. The company said it intends to use the net proceeds from this offering for working capital and general corporate purposes, but the dilution is weighing heavily on shares Wednesday morning.Stocktwits users are chatting about the stock’s sudden dip after Tuesday’s optimism. One user named “dt2011” pointed out the benefits of taking profits when opportunity allows.<figure class="image"><a href="https://stocktwits.com/dt2011/message/580521550"><img style="aspect-ratio:815/263;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_9_18_29_AM_8c732d9994.png" alt="Stocktwits user dt2011's post on Azitra Inc" width="815" height="263"></a><figcaption>Stocktwits user dt2011's post on Azitra Inc</figcaption></figure>

Azitra Stock Witnesses 220x Page Views On Stocktwits After These Developments 

The stock closed over 200% higher on Tuesday after the firm reported multiple patent wins. Still, investors are not very enthused with the company’s latest public offering worth $10 million

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

AZTR
Azitra Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AZTR News

AZTRAzitra Inc